title: [Interest of microalbuminuria in preventing kidney damage during systemic lupus erythematosus (SLE) under corticoid therapy].
abstract: This study aimed to evaluate the benefits of microalbuminuria in preventing kidney damage in systemic lupus erythemathosus. This was a prospective study of 6 months has focused on 25 patients of both sexes aged over 14 with SLE whose diagnosis was based on the criteria of the American College of Rheumatology, having a negative proteinuria at the dipstick (Ketodiastix(®)) and a balance sheet normal renal (creatinine and uraemia normal). Each month, samples of venous blood were achieved at the elbow in patients fasted for the night (12pm). The serum obtained was used for measurement of creatinine and urea, according to conventional methods, by a Hitachi 902(®) automated random type. The determination of urinary albumin by immuno-nephelometric method (Hitachi 902(®)), in search of microalbuminuria has involved the collection of urine over 24 hours in a sterile jar containing crystals of thymol as an antiseptic. In the presence of microalbuminuria, the dose of prednisone was progressively increased by 5 mg until no microalbuminuria. We found: 1) that creatinine and blood urea remained normal during the 6 months of study, 2) the disappearance of microalbuminuria first two months after increasing the daily dose of corticosteroid with a significant decrease of albuminuria from day 0 to day 180 (p = 0.001, day 180 vs day 0), 3) a female predominance with a sex ratio of 0.13. In conclusion, the regular dosage and systematic albuminuria to microalbuminuria appears to be a reliable means for diagnosis of lupus glomerulonephritis in the subclinical stage to prevent renal complications that occur during the Supported Lupus erythematosus.
authors.affiliation: UFR des sciences médicales, BPV166 Abidjan, Abidjan, Côte d'Ivoire.
authors.forename: Youzan
authors.initials: Y
authors.lastname: Ferdinand Djohan
authors.forename: Gervais
authors.initials: G
authors.lastname: Koffi
authors.forename: Ake Absalome
authors.initials: AA
authors.lastname: Monde
authors.forename: Germaine
authors.initials: G
authors.lastname: Niamke
authors.forename: Luc Dere
authors.initials: LD
authors.lastname: Kouadio
authors.forename: Georges
authors.initials: G
authors.lastname: Tiahou
authors.forename: Cisse
authors.initials: C
authors.lastname: Camara
authors.forename: Prosper
authors.initials: P
authors.lastname: Djessou
authors.forename: Daniel
authors.initials: D
authors.lastname: Sess
mesh_terms: D000419:Albuminuria / Q000150:complications* / Q000175:diagnosis*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D005938:Glucocorticoids; D011241:Prednisone